Key result
C-type natriuretic peptide reduces PVCs by ~15% versus amiodarone at 96 hours.
Why the study?
To compare the effect of C-type natriuretic peptide and amiodarone in Chinese patients with arrhythmia.
Does C-type natriuretic peptide reduce premature ventricular complexes compared to amiodarone in Chinese patients with arrhythmia?
RCT (n=200)
1:1
No
Does C-type natriuretic peptide reduce premature ventricular complexes compared to amiodarone in Chinese patients with arrhythmia?
C-type natriuretic peptide significantly reduces premature ventricular complexes and associated symptoms compared to amiodarone in Chinese patients.
Answers are grounded in this paper and cite their sources.
May reduce PVCs versus amiodarone; hypothesis-generating and leaves open confirmation in randomized trials.
Purpose: To compare the effect of C-type natriuretic peptide and amiodarone in Chinese patients with arrhythmia. Method: Chinese men and women aged 18 to 65 years with premature ventricular complexes (PVCs), were administered C-type natriuretic peptide (CNP) - test group or amiodarone (study group) in ratio of 1:1 for 96 h. Patients in CNP group received infusion of synthetic human CNP (10 pmol/kg/min) for an initial 2 h, and then for 30 min every day until discharge. Patients in amiodarone group received initial dose of 1000 mg over the first 24 h. Change in PVCs from baseline was the primary efficacy endpoint. Secondary efficacy endpoint includes: change in PVCs-related symptom scores from baseline, change in ejection fraction of left ventricle (LV), end‑diastolic diameter of LV, and cardiac events as composite outcome (CCE). The effect of both treatments on hemodynamic and electrocardiography parameters, and safety were evaluated. Data from 200 patients were analyzed. Results: The CNP showed significantly greater decrease in the number of PVCs when compared to amiodarone (p < 0.005). Moreover, CNP was superior in alleviating PVCs- related symptoms when compared to amiodarone (p < 0.005). A similar trend of favorable effect of CNP was observed for other endpoints. Conclusion: The C-type natriuretic peptide offers significantly greater benefits of suppressing PVCs and related symptoms, and demonstrates significantly greater improvement of cardiac function and clinical outcome. Thus, CNP can be considered for further investigation as a suitable alternative in the management of ventricular arrhythmia with PVC among Chinese patients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) conducted an RCT in Arrhythmia with premature ventricular complexes (n=200). C-type natriuretic peptide vs. Amiodarone was evaluated on Change in premature ventricular complexes (PVCs) from baseline (beats per 24 h at 96 h) (p=<0.005). C-type natriuretic peptide reduced the number of premature ventricular complexes at 96 hours compared to amiodarone in patients with arrhythmia.
Synapse has enriched 10 related papers. Consider them for comparative context: